Evidence map›Paper›PMID 40855072›Full record

ArticleNPJ vaccines2025

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study.

Sung K Chiu, Eliska Furlong, Elizabeth J McKinnon, Annette Fox, Stephany Sánchez Ovando, Louise Carolan, Andrew McLean-Tooke, Joyce Oommen, Daniel K Yeoh, Laurence C Cheung and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sung K Chiu *Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Eliska Furlong *Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Elizabeth J McKinnonLeukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Annette FoxWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Stephany Sánchez OvandoWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Louise CarolanWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Andrew McLean-TookeDepartment of Clinical Immunology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Joyce OommenLeukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Daniel K YeohDepartment of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, WA, Australia.
Laurence C CheungLeukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Nicholas G GottardoLeukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Rishi S KotechaLeukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia. rishi.kotecha@health.wa.gov.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule. This comprised three vaccine doses for children <9 years of age and two doses for those ≥9 years, with each dose administered at least 4 weeks apart. The additional vaccine dose was well-tolerated with no serious adverse events reported; it also resulted in improved geometric mean antibody titres for A/H1N1 (70 to 97, p = 0.003), A/H3N2 (76 to 104, p = 0.003) and B/Washington (148 to 179, p = 0.03) strains. In summary, a boosted influenza vaccine schedule is safe and improves humoral immune response, providing a readily implementable strategy to protect children undergoing treatment for cancer.

Identifiers

PMID40855072
PMCPMC12379222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.